Cysteine residues in the human cannabinoid receptor: Only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding

Biochemistry

Volumn 44, Issue 24, 2005, Pages 8757-8769

  Fay, Jonathan F ^a   Dunham, Thomas D ^a   Farrens, David L ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN; CELL MEMBRANES; METHANE; MUTAGENESIS; NEUROLOGY; SULFUR COMPOUNDS;

CYSTEIN; HUMAN CANNABINOID RECEPTORS (CB1); MARIJUANA; METHANETHIOSULFONATE (MTS);

PROTEINS;

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; AROMATIC COMPOUND; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CANNABIS; CYSTEINE; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; PIPERIDINE; PSYCHOTROPIC AGENT; RIMONABANT; SOLVENT; THIOL DERIVATIVE; THIOMESYLIC ACID METHYL ESTER;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BINDING SITE; CHEMICAL LABELING; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; LIGAND BINDING; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; SOLVATION; STEREOSPECIFICITY;

AMINO ACID SEQUENCE; BINDING SITES; CYSTEINE; DATABASES, PROTEIN; HUMANS; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PIPERIDINES; PROTEIN CONFORMATION; PYRAZOLES; RECEPTORS, CANNABINOID; SEQUENCE ALIGNMENT; SEQUENCE HOMOLOGY, AMINO ACID;

CANNABIS SATIVA;

EID: 20544465661     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi0472651     Document Type: Article

References (83)

1. Reggio, P. H. (2003) Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors. Curr. Pharm. Des. 9, 1607-1633.
2. Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Batkai, S., Jarai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., and Kunos, G. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake, Nature 410, 822-825.
3. Kreitzer, A. C., and Regehr, W. G. (2001) Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells, Neuron 29, 717-727.
4. Wilson, R. I., and Nicoll, R. A. (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588-592.
5. Ohno-Shosaku, T., Maejima, T., and Kano, M. (2001) Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals, Neuron 29, 729-738.
6. Cravatt, B. F., Giang, D. K., Mayfield, S. P., Boger, D. L., Lerner, R. A., and Gilula, N. B. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides, Nature 384, 83-87.
7. Di Marzo, V., Fontana, A., Cadas, H., Schinelli, S., Cimino, G., Schwartz, J. C., and Piomelli, D. (1994) Formation and inactivation of endogenous cannabinoid anandamide in central neurons, Nature 372, 686-691.
8. Stella, N., Schweitzer, P., and Piomelli, D. (1997) A second endogenous cannabinoid that modulates long-term potentiation, Nature 388, 773-778.
9. Andersson, H., D'Antona, A. M., Kendall, D. A., Von Heijne, G., and Chin, C. N. (2003) Membrane assembly of the cannabinoid receptor 1: Impact of a long N-terminal tail, Mol. Pharmacol. 64, 570-577.
10. Murphy, J. W., and Kendall, D. A. (2003) Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A, Biochem. Pharmacol. 65, 1623-1631.
11. Hurst, D. P., Lynch, D. L., Barnett-Norris, J., Hyatt, S. M., Seltzman. H. H., Zhong, M., Song, Z. H., Nie, J., Lewis, D., and Reggio, P. H. (2002) N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichorophenyl)-4-methyl-1H- pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol. 62, 1274-1287.
12. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor, Science 289, 739-745.
13. Karnik, S. S., and Khorana, H. G. (1990) Assembly of functional rhodopsin requires a disulfide bond between cysteine residues 110 and 187, J. Biol. Chem. 265, 17520-17524.
14. Ridge, K. D., Lu, Z., Liu, X., and Khorana, H. G. (1995) Structure and function in rhodopsin. Separation and characterization of the correctly folded and misfolded opsins produced on expression of an opsin mutant gene containing only the native intradiscal cysteine codons, Biochemistry 34, 3261-3267.
15. Hwa, J., Reeves, P. J., Klein-Seetharaman, J., Davidson, F., and Khorana, H. G. (1999) Structure and function in rhodopsin: Further elucidation of the role of the intradiscal cysteines, Cys-110, -185, and -187, in rhodopsin folding and function, Proc. Natl. Acad. Sci. U.S.A. 96, 1932-1935.
16. Hwa, J., Klein-Seetharaman, J., and Khorana, H. G. (2001) Structure and function in rhodopsin: Mass spectrometric identification of the abnormal intradiscal disulfide bond in misfolded retinitis pigmentosa mutants, Proc. Natl. Acad. Sci. U.S.A. 98, 4872-4876.
17. Lu, R., Hubbard, J. R., Martin, B. R., and Kalimi, M. Y. (1993) Roles of sulfhydryl and disulfide groups in the binding of CP-55,940 to rat brain cannabinoid receptor, Mol. Cell. Biochem. 121, 119-126.
18. Shire, D., Calandra, B., Delpech, M., Dumont, X., Kaghad, M., Le Fur, G., Caput, D., and Ferrara, P. (1996) Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A, J. Biol. Chem. 271, 6941-6946.
19. Francisco, M. E., Seltzman, H. H., Gilliam, A. F., Mitchell, R. A., Rider, S. L., Pertwee, R. G., Stevenson, L. A., and Thomas, B. F. (2002) Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)- 1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716), J. Med. Chem. 45, 2708-2719.
20. Ballesteros, J. A., and Weinstein, H. (1995) Integrated Methods for Modeling G-Protein Coupled Receptors, Methods Neurosci. 25, 366-428.
21. Farrens, D. L., Dunham, T. D., Fay, J. F., Dews, I. C., Caldwell, J., and Nauert, B. (2002) Design, expression, and characterization of a synthetic human cannabinoid receptor and cannabinoid receptor/G-protein fusion protein, J. Pept. Res. 60, 336-347.
22. Oprian, D. D., Molday, R. S., Kaufman, R. J., and Khorana, H. G. (1987) Expression of a synthetic bovine rhodopsin gene in monkey kidney cells. Proc. Natl. Acad. Sci. U.S.A. 84, 8874-8878.
23. Janz, J. M., Fay, J. F., and Farrens, D. L. (2003) Stability of dark state rhodopsin is mediated by a conserved ion pair in intradiscal loop E-2, J. Biol. Chem. 278, 16982-16991.
24. Swillens, S. (1995) Interpretation of binding curves obtained with high receptor concentrations: Practical aid for computer analysis, Mol. Pharmacol. 47, 1197-1203.
25. DeBlasi, A., O'Reilly, K., and Motulsky, H. J. (1989) Calculating receptor number from binding experiments using same compound as radioligand and competitor, Trends Pharmacol. Sci. 10, 227-229.
26. Javitch, J. A., Shi, L., and Liapakis, G. (2002) Use of the substituted cysteine accessibility method to study the structure and function of G protein-coupled receptors, Methods Enzymol. 343, 137-156.
27. Salo, O. M., Lahtela-Kakkonen, M., Gynther, J., Jarvinen, T., and Poso, A. (2004) Development of a 3D model for the human cannabinoid CB1 receptor, J. Med. Chem. 47, 3048-3057.
28. Singh, R., Hurst, D. P., Barnett-Norris, J., Lynch, D. L., Reggio, P. H., and Guarnieri, F. (2002) Activation of the cannabinoid CB1 receptor may involve a W6 48/F3 36 rotamer toggle switch, J. Pept. Res. 60, 357-370.
29. Gouldson, P., Calandra, B., Legoux, P., Kerneis, A., Rinaldi-Carmona, M., Barth, F., Le Fur, G., Ferrara, P., and Shire, D. (2000) Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor, Eur. J. Pharmacol. 401, 17-25.
30. Karnik, S. S., Ridge, K. D., Bhattacharya, S., and Khorana, H. G. (1993) Palmitoylation of bovine opsin and its cysteine mutants in COS cells, Proc. Natl. Acad. Sci. U.S.A. 90, 40-44.
31. Morrison, D. F., O'Brien, P. J., and Pepperberg, D. R. (1991) Depalmitylation with hydroxylamine alters the functional properties of rhodopsin. J. Biol. Chem. 266, 20118-20123.
32. Marin, E. P., Krishna, A. G., Zvyaga, T. A., Isele, J., Siebert, F., and Sakmar, T. P. (2000) The amino terminus of the fourth cytoplasmic loop of rhodopsin modulates rhodopsin-transducin interaction, J. Biol. Chem. 275, 1930-1936.
33. Hewlett, A. C., Song, C., Berglund, B. A., Wilken, G. H., and Pigg, J. J. (1998) Characterization of CB1 cannabinoid receptors using receptor peptide fragments and site-directed antibodies, Mol. Pharmacol. 53, 504-510.
34. Mukhopadhyay, S., Cowsik, S. M., Lynn, A. M., Welsh, W. J., and Howlett, A. C. (1999) Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane region: Structural requirements determined by peptide analysis, Biochemistry 38. 3447-3455.
35. Feng, W., and Song, Z. H. (2001) Functional roles of the tyrosine within the NP(X)(n)Y motif and the cysteines in the C-terminal juxtamembrane region of the CB2 cannabinoid receptor, FEBS Lett. 501, 166-170.
36. Roberts, D. D., Lewis, S. D., Ballou, D. P., Olson, S. T., and Shafer, J. A. (1986) Reactivity of small thiolate anions and cysteine-25 in papain toward methyl methanethiosulfonate, Biochemistry 25, 5595-5601.
37. Okada, T., Fujiyoshi, Y., Silow, M., Navarro, J., Landau, E. M., and Shichida, Y. (2002) Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography, Proc. Natl. Acad. Sci. U.S.A. 99, 5982-5987.
38. Wiley, J. L., Jefferson, R. G., Grier, M. C., Mahadevan, A., Razdan, R. K., and Martin, B. R. (2001) Novel pyrazole cannabinoids: Insights into CB(1) receptor recognition and activation, J. Pharmacol. Exp. Ther. 296, 1013-1022.
39. Lan, R., Liu, Q., Fan, P., Lin, S., Fernando, S. R., McCallion, D., Pertwee, R., and Makriyannis, A. (1999) Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists, J. Med. Chem. 42, 769-776.
40. McAllister, S. D., Rizvi, G., Anavi-Goffer, S., Hurst, D. P., Barnett-Norris, J., Lynch, D. L., Reggio, P. H., and Abood, M. E. (2003) An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region, J. Med. Chem. 46, 5139-5152.
41. Fu, D., Ballesteros, J. A., Weinstein, H., Chen, J., and Javitch, J. A. (1996) Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice, Biochemistry 35, 11278-11285.
42. Guan, X. M., Peroutka, S. J., and Kobilka, B. K. (1992) Identification of a single amino acid residue responsible for the binding of a class of β-adrenergic receptor antagonists to 5-hydroxytryptamine 1A receptors, Mol. Pharmacol. 41, 695-698.
43. Suryanarayana, S., Daunt, D. A., Von Zastrow, M., and Kobilka, B. K. (1991) A single point mutation in the seventh hydrophobic domain of the α2-adrenergic receptor changes antagonist binding specificity to that of a β receptor, Trans. Assoc. Am. Physicians 104, 62-68.
44. Suryanarayana, S., Daunt, D. A., Von Zastrow, M., and Kobilka, B. K. (1991) A point mutation in the seventh hydrophobic domain of the α2 adrenergic receptor increases its affinity for a family of β receptor antagonists. J. Biol. Chem. 266, 15488-15492.
45. Suryanarayana, S., and Kobilka, B. K. (1993) Amino acid substitutions at position 312 in the seventh hydrophobic segment of the β2-adrenergic receptor modify ligand-binding specificity, Mol. Pharmacol. 44, 111-114.
46. Roth, B. L., Shoham, M., Choudhary, M. S., and Khan, N. (1997) Identification of conserved aromatic residues essential for agonist binding and second messenger production at 5-hydroxytryptamine 2A receptors, Mol. Pharmacol. 52, 259-266.
47. Dawson, E. S., and Wells, J. N. (2001) Determination of amino acid residues that are accessible from the ligand binding crevice in the seventh transmembrane-spanning region of the human A(1) adenosine receptor, Mol. Pharmacol. 59, 1187-1195.
48. Simpson, M. M., Ballesteros, J. A., Chiappa, V., Chen, J., Suehiro, M., Hartman, D. S., Godel, T., Snyder, L. A., Sakmar, T. P., and Javitch, J. A. (1999) Dopamine D4/D2 receptor selectivity is determined by a divergent aromatic microdomain contained within the second, third, and seventh membrane-spanning segments, Mol. Pharmacol. 56, 1116-1126.
49. Xu, W., Chen, C., Huang, P., Li, J., de Kiel, J. K., Javitch, J. A., and Liu-Chen, L. Y. (2000) The conserved cysteine 7.38 residue is differentially accessible in the binding-site crevices of the μ, δ, and κ opoid receptors, Biochemistry 39, 13904-13915.
50. Rao, V. R., and Oprian, D. D. (1996) Activating mutations of rhodopsin and other G protein-coupled receptors, Annu. Rev. Biophys. Biomol. Struct. 25, 287-314.
51. Kim, J. M., Altenbach, C., Kono, M., Oprian, D. D., Hubbell, W. L., and Khorana, H. G. (2004) Structural origins of constitutive activation in rhodopsin: Role of the K296/E113 salt bridge, Proc. Natl. Acad. Sci. U.S.A. 101, 12508-12513.
52. Dryja, T. P., Berson, E. L., Rao, V. R., and Oprian, D. D. (1993) Heterozygous missense mutation in the rhodopsin gene as a cause of congenital stationary night blindness, Nat. Genet. 4, 280-283.
53. Robinson, P. R., Cohen, G. B., Zhukovsky, E. A., and Oprian, D. D. (1992) Constitutively active mutants of rhodopsin, Neuron 9, 719-725.
54. Tonacchera, M., Van Sande, J., Cetani, F., Swillens, S., Schvartz, C., Winiszewski, P., Portmann, L., Dumont, J. E., Vassart, G., and Parma, J. (1996) Functional characteristics of three new germline mutations of the thyrotropin receptor gene causing autosomal dominant toxic thyroid hyperplasia, J. Clin. Endocrinol. Metab. 81, 547-554.
55. Altenbach, C., Yang, K., Farrens, D. L., Farahbakhsh, Z. T., Khorana, H. G., and Hubbell, W. L. (1996) Structural features and light-dependent changes in the cytoplasmic interhelical E-F loop region of rhodopsin: A site-directed spin-labeling study. Biochemistry 35, 12470-12478.
56. Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., and Khorana, H. G. (1996) Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science 274, 768-770.
57. Sheikh, S. P., Zvyaga, T. A., Lichtarge, O., Sakmar, T. P., and Bourne, H. R. (1996) Rhodopsin activation blocked by metalion-binding sites linking transmembrane helices C and F, Nature 383, 347-350.
58. Gether, U., Lin, S., Ghanouni, P., Ballesteros, J. A., Weinstein, H., and Kobilka, B. K. (1997) Agonists induce conformational changes in transmembrane domains III and VI of the β2 adrenoceptor, EMBO J. 16, 6737-6747.
59. Dunham, T. D., and Farrens, D. L. (1999) Conformational changes in rhodopsin. Movement of helix f detected by site-specific chemical labeling and fluorescence spectroscopy, J. Biol. Chem. 274, 1683-1690.
60. Janz, J. M., and Farrens, D. L. (2004) Rhodopsin activation exposes a key hydrophobic binding site for the transducin α-subunit C terminus, J. Biol. Chem. 279, 29767-29773.
61. αi1-bound structures of IC3 and a mutant with altered G protein specificity, Protein Sci. 11, 2526-2531.
62. Yang, K., Farrens, D. L., Altenbach, C., Farahbakhsh, Z. T., Hubbell, W. L., and Khorana, H. G. (1996) Structure and function in rhodopsin. Cysteines 65 and 316 are in proximity in a rhodopsin mutant as indicated by disulfide formation and interactions between attached spin labels, Biochemistry 35, 14040-14046.
63. Hubbell, W. L., Altenbach, C., Hubbell, C. M., and Khorana, H. G. (2003) Rhodopsin structure, dynamics, and activation: A perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking, Adv. Protein Chem. 63, 243-290.
64. Alexiev, U., Rimke, I., and Pohlmann, T. (2003) Elucidation of the nature of the conformational changes of the EF-interhelical loop in bacteriorhodopsin and of the helix VIII on the cytoplasmic surface of bovine rhodopsin: A time-resolved fluorescence depolarization study, J. Mol. Biol. 328, 705-719.
65. Imamoto, Y., Kataoka, M., Tokunaga, F., and Palczewski, K. (2000) Light-induced conformational changes of rhodopsin probed by fluorescent alexa594 immobilized on the cytoplasmic surface, Biochemistry 39, 15225-15233.
66. Abdulaev, N. G., and Ridge, K. D. (1998) Light-induced exposure of the cytoplasmic end of transmembrane helix seven in rhodopsin, Proc. Natl. Acad. Sci. U.S.A. 95, 12854-12859.
67. Fritze, O., Filipek, S., Kuksa, V., Palczewski, K., Hofmann, K. P., and Ernst, O. P. (2003) Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation, Proc. Natl. Acad. Sci. U.S.A. 100, 2290-2295.
68. Shapiro, D. A., Kristiansen, K., Weiner, D. M., Kroeze, W. K., and Roth, B. L. (2002) Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6, J. Biol. Chem. 277, 11441-11449.
69. Ballesteros, J. A., Jensen, A. D., Liapakis, G., Rasmussen, S. G., Shi, L., Gether, U., and Javitch, J. A. (2001) Activation of the β2-adrenergic receptor involves disruption of an ionic lock between the cytoplasmic ends of transmembrane segments 3 and 6, J. Biol. Chem. 276, 29171-29177.
70. Gerber, B. O., Meng, E. C., Dotsch, V., Baranski, T. J., and Bourne, H. R. (2001) An activation switch in the ligand binding pocket of the C5a receptor, J. Biol. Chem. 276, 3394-3400.
71. Teller, D. C., Stenkamp, R. E., and Palczewski, K. (2003) Evolutionary analysis of rhodopsin and cone pigments: Connecting the three-dimensional structure with spectral tuning and signal transfer, FEBS Lett. 555, 151-159.
72. Karnik, S. S., Gogonea, C., Patil, S., Saad, Y., and Takezako, T. (2003) Activation of G-protein-coupled receptors: A common molecular mechanism, Trends Endocrinol. Metab. 14, 431-437.
73. Ballesteros, J. A., Shi, L., and Javitch, J. A. (2001) Structural mimicry in G protein-coupled receptors: Implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors, Mol. Pharmacol. 60, 1-19.
74. Visiers, I., Ballesteros, J. A., and Weinstein, H. (2002) Three-dimensional representations of G protein-coupled receptor structures and mechanisms, Methods Enzymol. 343, 329-371.
75. Swaminath, G., Xiang, Y., Lee, T. W., Steenhuis, J., Parnot, C., and Kobilka, B. K. (2004) Sequential binding of agonists to the β2 adrenoceptor. Kinetic evidence for intermediate conformational states, J. Biol. Chem. 279, 686-691.
76. Picone, R. P., Fournier, D. J., Makriyannis, A. (2002) Ligand based structural studies of the CB1 cannabinoid receptor. J. Pept. Res. 60, 348-356.
77. Bays, H. E. (2004) Current and investigational antiobesity agents and obesity therapeutic treatment targets, Obes. Res. 12, 1197-1211.
78. Karlin, A., and Akabas, M. H. (1998) Substituted-cysteine accessibility method, Methods Enzymol. 293, 123 -145.
79. Akabas, M. H., Stauffer, D. A., Xu, M., and Karlin, A. (1992) Acetylcholine receptor channel structure probed in cysteine-substitution mutants, Science 258, 307-310.
80. Shim, J. Y., Welsh, W. J., Cartier, E., Edwards, J. L., and Howlett, A. C. (2002) Molecular interaction of the antagonist N-(piperidin-1-y1)-5-(4- chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor, J. Med. Chem. 45, 1447-1459.
81. McAllister, S. D., Hurst, D. P., Barnett-Norris, J., Lynch, D., Reggio, P. H., and Abood, M. E. (2004) Structural mimicry in class A protein-coupled receptor rotamer toggle switches: The importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation, J. Biol. Chem. 279, 48024-48037.
82. Hsieh, C., Brown, S., Derleth, C., Mackie, K. (1999) Internalization and recycling of the CB1 cannabinoid receptor. J. Neurochem. 73, 493-501.
83. Luk, T., Jin, W., Zvonok, A., Lu, D., Lin, X. Z., Chavkin, C., Makriyannis, A., Mackie, K. (2004) Identification of a potent and highly efficacious, yet slowly desensitizing CB1 cannabinoid receptor agonist. Br. J. Pharmacol. 142, 495-500.